8-K: OmniAb Reports Q4 & Full Year 2025 Results, Guides 2026

OmniAb, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting decreased revenue but an expanded partner base and new technology launch.

Summary

• Revenue for the fourth quarter of 2025 was $8.4 million, a decrease from $10.8 million for the same period in 2024.
• Full year 2025 revenue was $18.7 million, down from $26.4 million for 2024.
• Net loss for the fourth quarter of 2025 was $14.2 million, or $0.11 per share, compared with a net loss of $13.1 million, or $0.12 per share, for Q4 2024.
• Net loss for the full year 2025 was $64.8 million, or $0.57 per share, compared with a net loss of $62.0 million, or $0.61 per share, for 2024.
• As of December 31, 2025, OmniAb had cash, cash equivalents and short-term investments of $54.0 million.
• The company exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs.
• OmniAb launched OmniUltra in December 2025, a new transgenic chicken engineered to express ultralong CDRH3 domains.
• Entered into new license agreements with Dana Farber Cancer Institute, Mabtrx Biosciences, and two global pharmaceutical companies during Q4 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with significant revenue declines and increasing net losses, offset by strong partner growth and promising new technology, but with a concerning cash burn outlook.

Positives

• Expanded base of 107 active partners and 407 active programs as of December 31, 2025, including 32 OmniAb-derived programs in clinical development or being commercialized.
• Launched OmniUltra, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, enabling isolation of picobodies.
• Strong interest in the xPloration partner access program, contributing $0.8 million in revenue for 2025.
• Several later-stage partner assets are emerging with potential for meaningful milestones and recurring royalty revenue.
• Net loss per share improved slightly in Q4 2025 ($0.11 vs $0.12 in Q4 2024) and full year 2025 ($0.57 vs $0.61 in 2024).
• Research and development expense decreased for the full year 2025 to $47.8 million from $55.1 million in 2024, primarily due to lower personnel and external expenses.
• General and administrative expense decreased for the full year 2025 to $29.2 million from $30.7 million in 2024, primarily due to lower legal fees and share-based compensation.
• Other operating income, net for 2025 included a $3.0 million gain from the sale of a small molecule Kv7.2 program.
• Entered new license agreements with Dana Farber Cancer Institute, Mabtrx Biosciences, and two global pharmaceutical companies.

Negatives

• Revenue for Q4 2025 decreased to $8.4 million from $10.8 million in Q4 2024, primarily due to a decline in license and service revenue.
• Revenue for full year 2025 decreased to $18.7 million from $26.4 million in 2024, primarily due to a $2.5 million decrease in license revenue and a $1.6 million decrease in milestone revenue.
• Net loss for Q4 2025 increased to $14.2 million from $13.1 million in Q4 2024.
• Net loss for full year 2025 increased to $64.8 million from $62.0 million in 2024.
• Research and development expense in Q4 2025 increased to $13.9 million from $13.3 million in Q4 2024, due to a $3.9 million impairment charge.
• A $3.9 million impairment charge was recorded, primarily related to certain small molecule ion channel property and equipment.
• Cash, cash equivalents and short-term investments decreased to $54.0 million as of December 31, 2025, from $59.4 million as of December 31, 2024.
• Projected 2026 revenue range of $25 million to $30 million is still relatively low given the expected operating expenses of $80 million to $85 million.
• Expected cash and cash equivalents to end 2026 in the range of $30 million to $35 million, indicating significant cash burn.

Risks

• Future operating results and success are dependent on acceptance of the technology platform and technologies by new and existing partners.
• Success is dependent on the eventual development, approval, and commercialization of products developed by partners, over which the company has no control over the development plan, regulatory strategy, or commercialization efforts.
• Biopharmaceutical development is inherently uncertain.
• Risks arise from changes in technology.
• The competitive environment in the life sciences and biotechnology platform market.
• Risks associated with quality and timing in manufacturing xPloration instruments and related consumables, and reliance on a limited number of third-party manufacturers and suppliers.
• Failure to maintain, protect, and defend intellectual property rights.
• Difficulties with performance of third parties relied on for business.
• Government healthcare reform, legislative measures, and regulatory developments in the United States and foreign countries.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.
• May not achieve financial guidance.
• Operating expenses may be higher than anticipated, including if the company engages in unplanned activities or faces unexpected, or higher than anticipated, expenses.
• May use capital resources sooner than expected.

Future Outlook

OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, with costs and operating expenses projected between $80 million and $85 million. Cash costs and operating expenses are anticipated to be $50 million to $55 million, and the company expects to end 2026 with cash and cash equivalents between $30 million and $35 million. The company also anticipates several partner clinical trial data readouts in 2026 and 2027, with Merck KGaA planning Phase 3 trials for precemtabart tocentecan in 2026.

Management Comments

• "OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs."
• "Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure."
• "As our partner pipeline continues to advance, several later-stage assets are emerging with potential to generate meaningful milestones and, ultimately, recurring royalty revenue."
• "Our focus on innovation was evident in the recent launch of OmniUltra, which strengthens our ability to attract new partners and service new programs."
• "Additionally, we continue to see strong interest in the xPloration partner access program and are excited about its contributions to the business."

Industry Context

StockSavvy.ai notes that OmniAb's focus on expanding its partner base and program portfolio, alongside the launch of innovative platforms like OmniUltra, positions it within the broader trend of biotechnology companies leveraging proprietary discovery platforms to drive drug development. The increasing number of programs in clinical development, including 32 OmniAb-derived programs, suggests a maturing pipeline, which is crucial for platform companies to demonstrate value and generate future royalty streams. The reported decline in license and service revenue, however, indicates a challenge in monetizing early-stage engagements or a shift in revenue mix, a common dynamic in the platform licensing model.

Comparison to Industry Standards

• The launch of OmniUltra, a transgenic chicken engineered to express ultralong CDRH3 domains and enable picobody isolation, represents a novel advancement in antibody discovery, potentially offering a competitive edge over traditional transgenic animal platforms like those from Regeneron (VelocImmune) or Harbour BioMed (Harbour Mice) by enabling smaller, more versatile binding domains.
• The expansion to 107 active partners and 407 active programs is a strong indicator of platform adoption, comparable to the growth seen by other leading antibody discovery platforms in their scaling phases, though the ultimate success hinges on the clinical progression and commercialization rates of these partnered programs.
• The funding agreement between Teva Pharmaceuticals and Royalty Pharma for TEV-'408, an anti-IL-15 antibody, highlights a growing industry trend where non-dilutive financing from royalty companies is used to accelerate clinical development, validating the potential of assets derived from platforms like OmniAb.
• The progression of partner assets like IMVT-1402 (Immunovant) and precemtabart tocentecan (Merck KGaA) into later-stage clinical trials (Phase 3) is a critical benchmark for antibody discovery platforms, demonstrating the ability to generate commercially viable drug candidates, similar to how AbCellera's platform has advanced multiple programs.

Stakeholder Impact

• Shareholders: Potential for future royalty revenue from advancing partner programs, but current financial performance shows revenue decline and increased net loss, alongside significant cash burn, which could impact share value.
• Partners: Benefit from new technologies like OmniUltra and xPloration, expanding the tools available for drug discovery.
• Employees: Reduced headcount mentioned as a factor in lower personnel expenses, indicating potential job impacts.

Next Steps

• Conference call with management today (March 4, 2026) at 4:30 p.m. Eastern time.
• Topline data for IMVT-1402 in difficult-to-treat rheumatoid arthritis expected in H2 2026.
• Topline data for IMVT-1402 in cutaneous lupus erythematosus expected in H2 2026.
• Topline data from two Phase 3 studies for batoclimab in thyroid eye disease expected in H1 2026.
• Topline results of Phase 1b trial for TEV-'408 in vitiligo expected in H1 2026.
• Topline results of Phase 2a trial for TEV-'408 in celiac disease expected in H2 2026.
• Merck KGaA plans to advance precemtabart tocentecan to Phase 3 trials in metastatic colorectal cancer, with study initiation anticipated in 2026.
• Topline data for IMVT-1402 in Graves disease and myasthenia gravis expected in 2027.

Key Dates

Recommendation

While OmniAb demonstrates strong operational progress with an expanded partner base, new technology launches, and several programs advancing to later clinical stages, the significant decline in 2025 revenue and increased net loss are concerning. The projected cash burn for 2026, leading to a lower year-end cash balance, suggests ongoing financial pressure. The long-term potential from royalties is attractive, but the immediate financial performance and cash position warrant a cautious "hold" stance until there is clearer evidence of revenue stabilization and a path to profitability or reduced cash burn.

Keywords

OmniAb, OABI, Financial Results, Biotechnology, Antibody Discovery, Transgenic Animals, OmniUltra, xPloration, SEC Filing, Earnings Report, Drug Development, Clinical Trials, Partnerships, Royalty Revenue